Intravenous Ferric Carboxymaltose in Heart Failure With Iron Deficiency
Deutsches Herzzentrum der Charité · German Centre for Cardiovascular Research · +45 more institutions
Abstract
Uncertainty remains about the efficacy of intravenous iron in patients with heart failure and iron deficiency.
To assess the efficacy and safety of ferric carboxymaltose in patients with heart failure and iron deficiency. Design, Setting, and Participants: This multicenter, randomized clinical trial enrolled 1105 patients with heart failure (defined as having a left ventricular ejection fraction of ≤45%) and iron deficiency (serum ferritin level
Citation impact
- FWCI
- 70.25
- Percentile
- 100%
- References
- 26
Authors
49- SDStefan D. AnkerCorresponding
Deutsches Herzzentrum der Charité, German Centre for Cardiovascular Research, Charité - Universitätsmedizin Berlin
- TFTim Friede
German Centre for Cardiovascular Research
- JBJaved Butler
Jackson Memorial Hospital, University of Mississippi Medical Center, Baylor Medical Center at Garland, Research Institute of Dallas
- KMKhawaja M. Talha
Loyola University Medical Center
- MPMarius Placzek
Topics & keywords
- Medicine
- Iron deficiency
- Heart failure
- Intravenous iron
- Internal medicine
- Gastroenterology
- Anemia
- Good health and well-being